Target Information

Target General Infomation
Target ID
T27186
Former ID
TTDC00176
Target Name
Placenta growth factor
Gene Name
PGF
Synonyms
PlGF-131; PGF
Target Type
Clinical Trial
Disease Macular degeneration [ICD9: 362.5; ICD10: H35.3]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Growth factor active in angiogenesisand endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.
BioChemical Class
Growth factor
Target Validation
T27186
UniProt ID
P49763
Sequence
MPVMRLFPCFLQLLAGLALPAVPPQQWALSAGNGSSEVEVVPFQEVWGRSYCRALERLVD
VVSEYPSEVEHMFSPSCVSLLRCTGCCGDENLHCVPVETANVTMQLLKIRSGDRPSYVEL
TFSQHVRCECRHSPGRQSPDMPGDFRADAPSFLPPRRSLPMLFRMEWGCALTGSQSAVWP
SSPVPEEIPRMHPGRNGKKQQRKPLREKMKPERCGDAVPRR
Drugs and Mode of Action
Drug(s) RO-5323441 Drug Info Phase 2 Solid tumours [523948]
R7334 Drug Info Phase 1 Macular degeneration [522356]
SFLT-01 Drug Info Phase 1 Macular degeneration [522879]
Inhibitor 2-Methyl-2,4-Pentanediol Drug Info [551393]
RO-5323441 Drug Info [549755]
Modulator SFLT-01 Drug Info [531341]
Pathways
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Focal adhesion
Pathways in cancer
NetPath Pathway TSH Signaling Pathway
Pathway Interaction Database VEGFR1 specific signals
Reactome VEGF ligand-receptor interactions
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Focal Adhesion
Signaling by VEGF
References
Ref 522356ClinicalTrials.gov (NCT00702494) Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours. U.S. National Institutes of Health.
Ref 522879ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health.
Ref 523948ClinicalTrials.gov (NCT01622764) 89Zr-RO5323441 PET Imaging in Glioblastoma. U.S. National Institutes of Health.
Ref 531341sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
Ref 549755RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 551607Clinical pipeline report, company report or official report of Roche (2009).